ArticleJournal of thrombosis and thrombolysis2026
Structural and functional disruption of fibrinogen by a novel FGG c.1099G > C (p.Ala367Pro) variant: an integrated in silico mechanistic study.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to elucidate the molecular pathogenesis of the novel FGG p.Ala367Pro variant, recently identified in a patient with congenital dysfibrinogenemia (CD), using an integrated in silico approach. A comprehensive computational pipeline was applied. Pathogenicity was evaluated using MutationTaster, PolyPhen-2, PROVEAN, and VarCards. Structural effects were modeled with AlphaFold3 and analyzed via PyMOL. Protein stability was assessed using Missense3D, DUET, MUpro, DynaMut2, and I-Mutant2.0. Evolutionary conservation was evaluated using ConSurf and Clustal X. The p.Ala367Pro variant was consistently predicted to be deleterious by all pathogenicity prediction tools. Structural modeling indicated that the alanine-to-proline substitution predicteda local alpha-helix and abolishes a key hydrogen bond, leading to significant destabilization of the γ-chain tertiary structure (consistently negative ΔΔG values across stability prediction tools). The Ala367 residue was found to be perfectly conserved across species. These findings support a potentially mechanistic that the FGG p.Ala367Pro mutation is a pathogenic variant that disrupts fibrinogen function by compromising γ-chain stability and structure. Our work establishes a in silico framework for the functional validation of novel fibrinogen variants, crucial for interpreting genetic findings and guiding clinical management in CD.
Indexed as
Identifiers
42859328What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.